Clinical Trials | April 22, 2026
Merck wins FDA priority review for KEYTRUDA bladder cancer combo expansion
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal
The launch coincides with IBS Awareness Month in April
The company stated that it will work closely with the regulator to address the observations within the stipulated timeframe
This development signals a cleanup of Anlon’s borrowing profile and closure of legacy debt facilities
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
With the expansion, the hospital’s total bed capacity will rise from 380 to 539 beds
Subscribe To Our Newsletter & Stay Updated
